5-(2-Hydroxypropan-2-yl)-2-methylcyclohexan-1-one | 7712-37-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 5-(2-Hydroxypropan-2-yl)-2-methylcyclohexan-1-one
• CAS: 7712-37-0
• 化学式: C₁₀H₁₈O₂
• 分子量: 170.252
• InChiKey: WZUYMVXZZRCRMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-bromo-1,8-dihydroxy-p-menthane 在 zinc sulfide 作用下， 以 二甲基亚砜 为溶剂， 反应 10.0h， 以62%的产率得到5-(2-Hydroxypropan-2-yl)-2-methylcyclohexan-1-one
  参考文献：
  名称：

  用硫化锌和DMSO将叔-β-溴代醇直接转化为酮。

  摘要：

  衍生自简单单萜碳氢化合物的叔-β-溴代醇与硫化锌在二甲亚砜中反应，生成饱和酮作为主要产物，羟基酮作为次要产物。该反应涉及DMSO对与卤素连接的碳的初始亲核攻击，这由亲电子硫化锌辅助。随后的Kornblum型氧化产生α-羟基酮。另一方面，将质子β提取至羟基，然后相邻的羟基部分攻击二甲基s氧ox中间体的硫，随后其崩溃，生成烯醇，其互变异构为饱和酮。主要遵循后一种途径。

  DOI：

  10.1021/jo020658q

文献信息

• A Mixture of diastereoisomer compounds, as obtained from (-)-5-(1-hydroxy-1-methylethyl)-2-methyl-2-cyclohexene-1-one, having mucose-cretolytic activity, a process for its preparation and pharmaceutical compositions containing the same
  申请人：CAMILLO CORVI S.p.A.

  公开号：EP0170839A2

  公开（公告）日：1986-02-12

  The object of the present invention are the following diastereoisomer compounds (as derived from (-)-5-(1-hydroxy-1-methylethyl)-2-methyl-2-cyclohexene-1-one): (I): (1 S-5 R) 5-hydroxy-a,a-4,5-tetramethyl-3-cyclohexene-1-methanol (CO/1516) (II): (1 S-5 S) 5-hydroxy-a,a-4,5-tetramethyl-3-cyclohexene-1-methanol (CO/1517) which can be separated from the mixture of (I) + (II) at the % proportion of 44.44/55.55; said mixture will be hereinafter also designated either by the code CO/1483 or by (III). This invention provides, furthermore, the process for obtaining the mixture (III) (CO/1483) by reaction of (-)-5-(1-hydroxy-1-methylethyl)-2-methyl-2-cyclohexene-1-one with methyl-lithium and for separating the diastereoisomers (I) and (II) by a chromatographic method. Finally, the present invention comprises pharmaceutical compositions which contain the compounds (I), (II) and the mixture (III), when possess a pharmacologic mucosecretolytic activity.

  本发明的目的是下列非对映异构体化合物（由 (-)-5-(1- 羟基-1-甲基乙基)-2-甲基-2-环己烯-1-酮衍生而来）： (I):(1 S-5 R) 5-羟基-a,a-4,5-四甲基-3-环己烯-1-甲醇 (CO/1516) (II)：(1 S-5 S) 5-羟基-a,a-4,5-四甲基-3-环己烯-1-甲醇（CO/1517），可从(I)+(II)的混合物中分离出来，比例为 44.44/55.55；该混合物在下文中也将以 CO/1483 或(III)命名。 此外，本发明还提供了通过(-)-5-(1-羟基-1-甲基乙基)-2-甲基-2-环己烯-1-酮与甲基-锂反应获得混合物(III)(CO/1483)的工艺，以及通过色谱法分离非对映异构体(I)和(II)的工艺。 最后，本发明包括含有化合物（I）、（II）和混合物（III）的药物组合物，它们具有药理上的粘液分泌溶解活性。
• CLIVE D. L. J.; CHITTATTU G. J.; FARINA V.; KIEL W. A.; MENCHEN S. M.; RU+, J. AMER. CHEM. SOC., 1980, 102, NO 13, 4438-4447
  作者：CLIVE D. L. J.、 CHITTATTU G. J.、 FARINA V.、 KIEL W. A.、 MENCHEN S. M.、 RU+

  DOI：——

  日期：——
• SEMISCH C.; MARGARETHA P., J. FLUOR. CHEM., 34,(1986) N 1, 105-115
  作者：SEMISCH C.、 MARGARETHA P.

  DOI：——

  日期：——
• METHOD FOR TREATING AN AUTOIMMUNE NEUROLOGICAL DISEASE AND/OR NEURODEGENERATIVE DISEASE AND PHARMACEUTICAL FORMULATIONS FOR A LIQUID DOSAGE FORM AND A CONTROLLED RELEASE DOSAGE FORM
  申请人：INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

  公开号：US20190000776A1

  公开（公告）日：2019-01-03

  A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: wherein is a single or double bond, X is NCH 3 or CH 2 , Y is null, O or N, R 1 is H, OH, and R 2 is null, H, C 1 -C 8 alkyl, —(C═O)-alkyl, —(C═O)-aryl, —(C═O)-alkyl-aryl, —(C═O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO 2 , —NH 2 , —NR 3 R 4 , carbonyl, alkoxyl, alkyl or —OCF 3 , wherein R 3 and R 4 independently are H, alkyl, —SO 2 CH 3 , —(C═O)—CH 3 or —(C═O)—NH 2 .
• MULTI-PARTICULATE PHARMACEUTICAL COMPOSITION, IMMEDIATE RELEASE PELLETS, SUSTAINED RELEASE PELLETS, ENTERIC RELEASE PELLETS AND USE THEREOF
  申请人：Industrial Technology Research Institute

  公开号：US20210290557A1

  公开（公告）日：2021-09-23

  A multi-particulate pharmaceutical composition includes mixture pellets including at least two of the following pellets: a first immediate-release pellet, a sustained-release pellet, an enteric-release pellet and an enteric coated sustained-release pellet.